Rare but Severe Lung Inflammation Linked to BC Drugs

Moderators

FDA Warns About Rare but Severe Lung Inflammation Linked to Breast Cancer Drugs Ibrance, Kisqali, and Verzenio
September 17, 2019
On Sept. 13, 2019, the FDA released a statement warning about a link between rare but severe lung inflammation and the three CDK4/6 inhibitors used to treat advanced-stage hormone-receptor-positive, HER2-negative breast cancer. Read more...